• Home
  • Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide.

Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide.

Author List
Polley MY, Lamborn KR, Chang SM, Butowski N, Clarke JL, Prados M
Publication
Neuro-oncology
Publication ID (Profile URL)
https://researcherprofiles.org/profile/1474432
Publication Year
2009
PubMed ID
20167815
Publication Title
Polley MY, Lamborn KR, Chang SM, Butowski N, Clarke JL, Prados M. Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide. Neuro Oncol. 2010 Mar; 12(3):274-82.